The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab has demonstrated improvements in progression-free survival. A recent trial showed that maintenance therapy involving a PARP inhibitor improved overall survival in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations.
In this enduring activity, an expert will examine relevant advances in genetic biomarker testing to individualize therapy, assess recent efficacy and safety data related to PARP inhibitors and bevacizumab maintenance therapy, and review strategies to effectively prevent and manage adverse effects.
Faculty : Ursula Matulonis, MD
Click here to participate: